Patent information
IP India · live recordAbstract
A method of inducing an antigen-specific immune response in a mammalian subject includes the steps of administering to the subject an effective amount of a first composition comprising a DNA plasrnid comprising a DNA sequence encoding an antigen undet the cuntrol of regulatoty sequences directing expression thereof in a mammalian or vertcbrale cell. The method also includes administering to ihe subject an effective an muni of a second composition comprising a recombinant vesicular stomal itis vims (iVSV) comprising a nucleic acid sequence encoding the antigen under the control of regulator)' sequences directing expression thereof in the mammalian or vertebrate cell. The rVSV is in one embodiment replication competent. Kits for use in immunizations and therapeutic treatments of disease include the components and instructions for practice of this method.
Applicants
1Inventors
4Specification
Show full textCollapse
This invention was supported in part by funds from the United States government (National Institutes of Health, Grant Nos. NTH NOl-AJ 05397 and NTH NOl -AI2545S). Tire United States government may therefore have certain rights iu this invention. BACKGROUND OF THE INVENTION To enhance the efficacy of immunogenic compositions, a variety of immunogenic compositions and methods have been reported using protein compositions, plasmid-based compositions, and recombinant virus constructs as immunogenic compositions. Prior studies have demonstrated that plasmid-based immunogenic compositions, upon systemic application, prime the systemic immune system to a second systemic immunization with a traditional antigen, such as a protein or a recombinant virus (See, e.g., Xiang et al, 1997 Springer Semin. Immunopaihol, 79:257-268; Schneider, J. et al, 1998 Nature Med, 4:397; and Sedeguh, M. et al, 1998 Proc. Natl. Acad, Set, USA, 95:7648; Rogers, W. O. et al, 2001 Infec. &Immun., o"9(9):5565-72; Eo, S. K., etal, 2001 J. Immunol., 166(9):5473-9; Ramshaw I. A. and Ramsay, A. J., 2000 Immunol. Today, 27(4): 163- 5). An often used DNA prime/live vector boost regimen involves vaccinia viruses for the boost. Examples in the recent literature include such immunization for human immunodeficiency virus (HIV) (Ilanke T. et al, 2002 Vaccine. 20(15): 1995-8; Arnara R.R. et al, 2002 Vaccine. 20(15): 1949-55; Wee E.G. etal, 2002 J. Gen. Virol, 83(?t l):75-80; Amara R.R. et al, 2001 Science. 292(5514):69- 74). Prime-boost immunizations with DNA and modified vaccinia virus vectors expressing antigens such as herpes simplex virus-2 glycoprotein D, Leishmania infantum P36/LACK antigen, Plasmodium falciparum TRAP antigen, HlV/SrV antigens, murine tuberculosis antigens, and influenza antigens, have been reported to elicit specific antibody and cytokine responses (See, e.g., Meseda C.A. et al., 2002 J. Infect. Dis., 7